{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:45:41Z","timestamp":1780325141087,"version":"3.54.1"},"reference-count":94,"publisher":"Ordem dos Medicos","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Port"],"abstract":"<jats:p>As pessoas mais velhas s\u00e3o mais suscet\u00edveis a infe\u00e7\u00f5es e apresentam maior risco de complica\u00e7\u00f5es graves, com pior progn\u00f3stico funcional e vital. A vacina\u00e7\u00e3o \u00e9 uma estrat\u00e9gia eficaz e com perfil de seguran\u00e7a favor\u00e1vel na preven\u00e7\u00e3o de infe\u00e7\u00f5es, contribuindo para um envelhecimento saud\u00e1vel. Considerando a evid\u00eancia cl\u00ednica e as vacinas dispon\u00edveis em Portugal no primeiro semestre de 2025, o N\u00facleo de Estudos de Geriatria da Sociedade Portuguesa de Medicina Interna apresenta uma proposta de vacina\u00e7\u00e3o nos adultos com idade igual ou superior a 65 anos e alerta para a necessidade de criar um programa nacional de vacina\u00e7\u00e3o ao longo da vida que inclua as pessoas mais velhas, para aumentar a cobertura vacinal e diminuir o impacto das infe\u00e7\u00f5es nesta popula\u00e7\u00e3o. Embora o documento foque as pessoas com idade igual ou superior a 65 anos, a vacina\u00e7\u00e3o contra algumas doen\u00e7as deve come\u00e7ar mais cedo. Este artigo elabora cinco recomenda\u00e7\u00f5es principais: 1) Vacina\u00e7\u00e3o anual contra a gripe e a COVID-19 em todos os adultos com idade igual ou superior a 50 anos, devendo aqueles com idade igual ou superior a 65 anos receber a vacina trivalente de dose elevada contra a gripe; 2) Vacina\u00e7\u00e3o contra o v\u00edrus sincicial respirat\u00f3rio em todos os adultos com idade igual ou superior a 60 anos e adultos com 18 - 59 anos com fatores de risco, priorizando pessoas com idade igual ou superior a 75 anos e aqueles com idade igual ou superior a 50 anos com fatores de risco; 3) Vacina\u00e7\u00e3o com a vacina pneumoc\u00f3cica conjugada 20-valente ou 21-valente em todos os adultos com idade igual ou superior a 50 anos e adultos com 18 - 49 anos com fatores de risco; 4) Vacina\u00e7\u00e3o com a vacina recombinante contra o herpes zoster em todos os adultos com idade igual ou superior a 50 anos e adultos com 18 - 49 anos com risco elevado de herpes zoster; 5) A partir dos 65 anos, vacina\u00e7\u00e3o de refor\u00e7o contra o t\u00e9tano, difteria e tosse convulsa de 10 em 10 anos.<\/jats:p>","DOI":"10.20344\/amp.23786","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:57:44Z","timestamp":1767632264000},"page":"223-234","source":"Crossref","is-referenced-by-count":1,"title":["Vacina\u00e7\u00e3o de Adultos Mais Velhos em Portugal: Recomenda\u00e7\u00f5es do N\u00facleo de Estudos de Geriatria da Sociedade Portuguesa de Medicina Interna"],"prefix":"10.20344","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4879-559X","authenticated-orcid":false,"given":"Paulo Ricardo","family":"Sousa Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-3665","authenticated-orcid":false,"given":"Gon\u00e7alo","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-1917","authenticated-orcid":false,"given":"Heidi","family":"Gruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-6744","authenticated-orcid":false,"given":"Rafaela","family":"Ver\u00edssimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-5650","authenticated-orcid":false,"given":"Sofia","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8464","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"11708","unstructured":"Eurostat. Healthy life years statistics. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Healthy_life_years_statistics#Healthy_life_years_at_birth."},{"key":"11709","unstructured":"Eurostat. Population structure and ageing. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Population_structure_and_ageing."},{"key":"11710","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00717"},{"key":"11711","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.11.002"},{"key":"11712","doi-asserted-by":"publisher","DOI":"10.1159\/000504491"},{"key":"11713","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00118"},{"key":"11714","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2017.08.006"},{"key":"11715","unstructured":"Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones de vacunaci\u00f3n para adultos y mayores 2024-2025. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.segg.es\/pdfViewer\/web\/viewer.asp?archivo=vacunacion2024-2025."},{"key":"11716","unstructured":"El Banhawi H, Chowdhury S, Neri M, Radu P, Hodgson S, Bell E, et al. Socio-economic value of adult immunisation programmes. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ohe.org\/publications\/the-socio-economic-value-of-adult-immunisation-programmes\/."},{"key":"11717","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Norma N.o 18\/2020 de 27\/09\/2020. Programa nacional de vacina\u00e7\u00e3o 2020. 2020. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.dgs.pt\/normas-orientacoes-e-informacoes\/normas-e-circulares-normativas\/norma-n-0182020-de-27092020-pdf.aspx."},{"key":"11718","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Norma N.o 13\/2024 de 19\/12\/2024. Atualiza\u00e7\u00e3o da estrat\u00e9gia de vacina\u00e7\u00e3o pneumoc\u00f3cica \u2013 programa nacional de vacina\u00e7\u00e3o e grupos de risco. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.dgs.pt\/normas-orientacoes-e-informacoes\/normas-e-circulares-normativas\/norma-0132024-de-19122024-atualizacao-da-estrategia-de-vacinacao-pneumococica-programa-nacional-de-vacinacao-e-grupos-de-risco-pdf.aspx."},{"key":"11719","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Norma N.o 07\/2024 de 04\/09\/2024, atualizada a 07\/03\/2025. Campanha de vacina\u00e7\u00e3o sazonal contra a gripe: outono-inverno 2024-2025. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.dgs.pt\/normas-orientacoes-e-informacoes\/normas-e-circulares-normativas\/norma-n-072024-de-04092024-atualizada-a-07032025-campanha-de-vacinacao-sazonal-contra-a-gripe-outono-inverno-2024-2025-pdf.aspx."},{"key":"11720","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Norma N.o 08\/2024 de 05\/09\/2024, atualizada a 13\/12\/2024. Estrat\u00e9gia de vacina\u00e7\u00e3o contra a COVID-19. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.dgs.pt\/normas-orientacoes-e-informacoes\/normas-e-circulares-normativas\/norma-n-082024-de-05092024-atualizada-a-13122024-estrategia-de-vacinacao-contra-a-covid-19-pdf.aspx."},{"key":"11721","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07713-8"},{"key":"11722","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2023.11.003"},{"key":"11723","unstructured":"Infarmed. Efluelda tetra: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11724","unstructured":"Infarmed. Fluarix tetra: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11725","unstructured":"Infarmed. Influvac tetra: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11726","unstructured":"Infarmed. Vaxigrip tetra: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11727","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200206"},{"key":"11728","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2024-2025\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season.pdf?sfvrsn=2e9d2194_7&download=true."},{"key":"11729","unstructured":"Infarmed. Fluarix: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28 jul]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11730","unstructured":"Infarmed. Influvac: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11731","unstructured":"Infarmed. Vaxigrip: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11732","unstructured":"Infarmed. Efluelda: resumo das caracter\u00edsticas do medicamento. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11733","unstructured":"European Medicines Agency. Fluad: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/fluad-epar-product-information_pt.pdf."},{"key":"11734","unstructured":"European Medicines Agency. Flucelvax: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/flucelvax-epar-product-information_pt.pdf."},{"key":"11735","unstructured":"Centers for Disease Control and Prevention. Influenza (Flu) - ACIP recommendations summary. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.cdc.gov\/flu\/hcp\/acip\/index.html."},{"key":"11736","unstructured":"Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/downloads\/adult\/adult-combined-schedule.pdf."},{"key":"11737","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge. Boletim de vigil\u00e2ncia epidemiol\u00f3gica da gripe e outros v\u00edrus respirat\u00f3rios - \u00e9poca 2024\/2025 - semana 21 | 19 a 25 maio. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.insa.min-saude.pt\/wp-content\/uploads\/2025\/05\/S21_2025.pdf."},{"key":"11738","unstructured":"Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html."},{"key":"11739","unstructured":"European Medicines Agency. Comirnaty: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf."},{"key":"11740","unstructured":"European Medicines Agency. Spikevax: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/spikevax-epar-product-information_pt.pdf."},{"key":"11741","unstructured":"European Medicines Agency. Kostaive: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/kostaive-epar-product-information_pt.pdf."},{"key":"11742","unstructured":"European Medicines Agency. Bimervax: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/bimervax-epar-product-information_pt.pdf."},{"key":"11743","unstructured":"European Medicines Agency. Nuvaxovid: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/nuvaxovid-epar-product-information_pt.pdf."},{"key":"11744","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01230-3"},{"key":"11745","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa361"},{"key":"11746","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00919-w"},{"key":"11747","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10122092"},{"key":"11748","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit471"},{"key":"11749","unstructured":"Fonseca MJ, Reeves R, Pliakas T, Lopes R, Sim\u00e3o P, Coelho A, et al. Clinical and economic burden of respiratory syncytial virus among adults hospitalized with acute respiratory infections in Portugal. Poster apresentado no International RSV Symposium 2025, 12-15 mar; 2025; Iguazu, Brasil."},{"key":"11750","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad189"},{"key":"11751","unstructured":"European Medicines Agency. mRESVIA: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/mresvia-epar-product-information_pt.pdf."},{"key":"11752","unstructured":"European Medicines Agency. Arexvy: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/arexvy-epar-product-information_pt.pdf."},{"key":"11753","unstructured":"European Medicines Agency. Abrysvo: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/abrysvo-epar-product-information_pt.pdf."},{"key":"11754","unstructured":"Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. The efficacy of a single dose of the respiratory syncytial virus prefusion F protein vaccine in adults \u226560 years of age over 3 RSV seasons. Poster 3391 apresentado no CHEST 2024, 6-9 out; 2024; Boston, EUA."},{"key":"11755","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2311560"},{"key":"11756","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01738-0"},{"key":"11757","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.15775"},{"key":"11758","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.50832"},{"key":"11759","doi-asserted-by":"publisher","DOI":"10.1080\/25310429.2025.2451456"},{"key":"11760","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12091118"},{"key":"11761","unstructured":"Adult Immunization Board. RSV specific topic: need for revaccination? When and how to organize it?. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.adultimmunizationboard.org\/wp-content\/uploads\/2025\/05\/RSV-Specific-topic-Need-for-revaccination-When-and-how-to-organize-it.pdf."},{"key":"11762","unstructured":"European Centre for Disease Prevention and Control. Factsheet for health professionals about pneumococcal disease. 2023. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ecdc.europa.eu\/en\/pneumococcal-disease\/facts."},{"key":"11763","unstructured":"Grupo de Doen\u00e7as Respirat\u00f3rias da Associa\u00e7\u00e3o Portuguesa de Medicina Geral e Familiar (GRESP). A doen\u00e7a pneumoc\u00f3cica e recomenda\u00e7\u00f5es para a vacina\u00e7\u00e3o antipneumoc\u00f3cica na popula\u00e7\u00e3o adulta (\u226518 anos). 2022. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/gresp.pt\/ficheiros\/recursos\/folhetos\/recomendacoes-gresp-vacinacao-anti-pneumococica.pdf."},{"key":"11764","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073704"},{"key":"11765","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2019.10.003"},{"key":"11766","unstructured":"European Medicines Agency. Prevenar 13: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/prevenar-13-epar-product-information_pt.pdf."},{"key":"11767","unstructured":"European Medicines Agency. Vaxneuvance: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/vaxneuvance-epar-product-information_pt.pdf."},{"key":"11768","unstructured":"European Medicines Agency. Prevenar 20: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/prevenar-20-epar-product-information_pt.pdf."},{"key":"11769","unstructured":"European Medicines Agency. Capvaxive: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/capvaxive-epar-product-information_pt.pdf."},{"key":"11770","unstructured":"Infarmed. Pneumovax 23: resumo das caracter\u00edsticas do medicamento. 2022. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11771","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.01.014"},{"key":"11772","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab990"},{"key":"11773","doi-asserted-by":"publisher","DOI":"10.32385\/rpmgf.v39i6.13548"},{"key":"11774","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9051016"},{"key":"11775","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1279656"},{"key":"11776","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7401a1"},{"key":"11777","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.032"},{"key":"11778","unstructured":"UK Health Security Agency. Immunisation against infectious disease - the green book. Chapter 25 - pneumococcal. 2023. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/assets.publishing.service.gov.uk\/media\/64d68d6edd15ff000d278019\/Green_Book_Chapter_25_Pneumococcal_27_7_23.pdf."},{"key":"11779","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"11780","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa005"},{"key":"11781","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade. Avalia\u00e7\u00e3o do programa nacional de vacina\u00e7\u00e3o - 2o inqu\u00e9rito serol\u00f3gico nacional portugal continental 2001\u20132002. 2004. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.dgs.pt\/upload\/membro.id\/ficheiros\/i009552.pdf."},{"key":"11782","unstructured":"Silva F, Castanheira RC, Zarkadoulas E, Figueira D, Bulhosa C, Borges M, et al. Landscape of herpes zoster infections in Portugal. Poster apresentado no Encontro de Outono 2024 da APMGF, 21-23 nov; 2024; F\u00e1tima, Portugal."},{"key":"11783","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.709"},{"key":"11784","unstructured":"European Medicines Agency. Shingrix: EPAR - product information. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/pt\/documents\/product-information\/shingrix-epar-product-information_pt.pdf."},{"key":"11785","unstructured":"Duque S, Marinho A, Almeida P, Marques Pereira R, Buzaco R. Recomenda\u00e7\u00f5es para a vacina\u00e7\u00e3o contra o herpes zoster: documento de consenso da Sociedade Portuguesa de Medicina Interna e da Associa\u00e7\u00e3o Portuguesa de Medicina Geral e Familiar. Med Interna. 2023;30:180-91."},{"key":"11786","unstructured":"Infomed. Detalhes do medicamento: zostavax. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11787","unstructured":"American Academy of Ophthalmology. Recommendations for herpes zoster vaccine for patients 50 years of age and older. Ophthalmology. 2018;125:1813-6."},{"key":"11788","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.08.051"},{"key":"11789","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.029"},{"key":"11790","unstructured":"Infarmed. Boostrix: resumo das caracter\u00edsticas do medicamento. 2023. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11791","unstructured":"Infarmed. Triaxis: resumo das caracter\u00edsticas do medicamento. 2022. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11792","unstructured":"Infarmed. D.T. vax adulto: resumo das caracter\u00edsticas do medicamento. 2022. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11793","unstructured":"Infarmed. diTeBooster: Resumo das caracter\u00edsticas do medicamento. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/extranet.infarmed.pt\/INFOMED-fo\/index.xhtml."},{"key":"11794","unstructured":"European Centre for Disease Prevention and Control. Increase in pertussis cases in EU\/EEA: infants under six months of age at the highest risk. 2024. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.ecdc.europa.eu\/en\/news-events\/increase-pertussis-cases-eueea-infants-under-six-months-age-highest-risk."},{"key":"11795","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2324547"},{"key":"11796","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2018.1457796"},{"key":"11797","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00774-5"},{"key":"11798","unstructured":"European Centre for Disease Prevention and Control. Vaccine scheduler - pertussis: Recommended vaccinations. 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=3&SelectedCountryIdByDisease=-1."},{"key":"11799","unstructured":"International Federation on Ageing and European Geriatric Medicine Society. Statement of action \u2013 supporting a life course approach within national immunization technical advisory groups (NITAGs). 2025. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.vaccines4life.com\/wp-content\/uploads\/2025\/01\/IFA-EuGMS-Statement-1.pdf."},{"key":"11800","unstructured":"World Health Organization. Immunization agenda 2030. 2019. [consultado 2025 jul 28]. Dispon\u00edvel em: https:\/\/www.immunizationagenda2030.org."},{"key":"11801","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00874-4"}],"container-title":["Acta M\u00e9dica Portuguesa"],"original-title":[],"link":[{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/23786\/15853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/23786\/15857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:43:27Z","timestamp":1772469807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/view\/23786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":94,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.20344\/amp.23786","relation":{},"ISSN":["1646-0758","0870-399X"],"issn-type":[{"value":"1646-0758","type":"electronic"},{"value":"0870-399X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}